Seeking AlphaWed, 20 May 2026 02:10:44 GMTProtara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations TranscriptTARA+0.62%
BenzingaFri, 15 May 2026 15:36:29 GMTProtara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer StudyTARA+0.62%